Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BHVNBullishCorporate Developmentsnews

High materiality9/10

Biohaven-Ono Asia license: $80M upfront, 20% royalties, non-dilutive cash

Oct 8, 2026, 5:49 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Non-dilutive upfront cash and a defined royalty stream reduce equity risk; milestone potential within a year provides near-term upside catalysts; regional collaboration expands market access for BHVN's lead program.

AI summary

What happened, with direct paths to the underlying reporting

Biohaven and Ono Announced an exclusive Asia license for BHV-1300 and follow-ons, with up to $100 million in near-term payments and about 20% royalties on Ono's net sales in the territory. Biohaven retains rights outside Asia, including the US, Europe, and China, providing non-dilutive capital and potential long-term upside as BHV-1300 advances in Graves' disease and other IgG-mediated conditions.

Biohaven and Ono strike exclusive Asia license for MoDE degraders BHV-1300, 1310, 1320.
Ono pays up to $100m: $80m upfront, $20m milestone within a year.
Biohaven earns ~20% royalties on Ono net sales in licensed markets.
BHVN retains rights outside Asia, including US, Europe, and China.
First regional collaboration for an extracellular protein degrader.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.